Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.

Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE.

Epilepsia. 2019 Aug;60(8):1586-1592. doi: 10.1111/epi.16093. Epub 2019 Jun 27. Erratum in: Epilepsia. 2019 Sep;60(9):2009.

PMID:
31247132
2.

Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2019 Jun;41(3):357-370. doi: 10.1097/FTD.0000000000000583.

PMID:
30520828
3.

Iron supplements in nursing home patients associated with reduced carbamazepine absorption.

Ahn JE, Bathena SPR, Brundage RC, Conway JM, Leppik IE, Birnbaum AK.

Epilepsy Res. 2018 Nov;147:115-118. doi: 10.1016/j.eplepsyres.2018.07.015.

PMID:
30327119
4.

Status epilepticus in the elderly.

Leppik IE.

Epilepsia. 2018 Oct;59 Suppl 2:140-143. doi: 10.1111/epi.14497. Epub 2018 Aug 29.

5.

Individual Differences in Working Memory Capacity Predict Topiramate-Related Cognitive Deficits.

Barkley CM, Hu Z, Fieberg AM, Eberly LE, Birnbaum AK, Leppik IE, Marino SE.

J Clin Psychopharmacol. 2018 Oct;38(5):481-488. doi: 10.1097/JCP.0000000000000949.

6.

Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age.

Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, Ramsay RE, Kistner BM, Birnbaum AK.

Epilepsia. 2018 Sep;59(9):1718-1726. doi: 10.1111/epi.14519. Epub 2018 Aug 12.

7.

Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy.

Conway JM, Eberly LE, Collins JF, Macias FM, Ramsay RE, Leppik IE, Birnbaum AK.

Pharmacotherapy. 2017 Oct;37(10):1197-1203. doi: 10.1002/phar.2012. Epub 2017 Sep 19.

PMID:
28801938
8.

Antiseizure, antidepressant, and antipsychotic medication prescribing in elderly nursing home residents.

Bathena SPR, Leppik IE, Kanner AM, Birnbaum AK.

Epilepsy Behav. 2017 Apr;69:116-120. doi: 10.1016/j.yebeh.2017.01.027. Epub 2017 Feb 24.

9.

Prevalence of epilepsy/seizures as a comorbidity of neurologic disorders in nursing homes.

Birnbaum AK, Leppik IE, Svensden K, Eberly LE.

Neurology. 2017 Feb 21;88(8):750-757. doi: 10.1212/WNL.0000000000003629. Epub 2017 Jan 20.

10.

Pharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients.

Ahmed GF, Bathena SP, Brundage RC, Leppik IE, Conway JM, Schwartz JB, Birnbaum AK.

AAPS J. 2017 Mar;19(2):551-556. doi: 10.1208/s12248-016-0022-z. Epub 2017 Jan 9.

PMID:
28070716
11.

Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy.

Vuu I, Coles LD, Maglalang P, Leppik IE, Worrell G, Crepeau D, Mishra U, Cloyd JC, Patterson EE.

Front Vet Sci. 2016 Dec 5;3:107. eCollection 2016.

12.

Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies.

Leppik IE, Yang H, Williams B, Zhou S, Fain R, Patten A, Bibbiani F, Laurenza A.

Epilepsia. 2017 Jan;58(1):51-59. doi: 10.1111/epi.13600. Epub 2016 Nov 21.

13.

Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Patel SI, Birnbaum AK, Cloyd JC, Leppik IE.

CNS Drugs. 2015 Dec;29(12):1009-22. doi: 10.1007/s40263-015-0289-0. Review.

PMID:
26603741
14.

Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers.

Lim CN, Birnbaum AK, Brundage RC, Leppik IE, Cloyd JC, Clark A, Marino SE.

J Clin Pharmacol. 2016 Jun;56(6):714-22. doi: 10.1002/jcph.646. Epub 2015 Dec 21.

15.

Third International Congress on Epilepsy, Brain and Mind: Part 1.

Korczyn AD, Schachter SC, Amlerova J, Bialer M, van Emde Boas W, Brázdil M, Brodtkorb E, Engel J Jr, Gotman J, Komárek V, Leppik IE, Marusic P, Meletti S, Metternich B, Moulin CJ, Muhlert N, Mula M, Nakken KO, Picard F, Schulze-Bonhage A, Theodore W, Wolf P, Zeman A, Rektor I.

Epilepsy Behav. 2015 Sep;50:116-37. doi: 10.1016/j.yebeh.2015.06.044. Epub 2015 Aug 11. Review.

16.

Intramuscular and rectal therapies of acute seizures.

Leppik IE, Patel SI.

Epilepsy Behav. 2015 Aug;49:307-12. doi: 10.1016/j.yebeh.2015.05.001. Epub 2015 Jun 11. Review.

PMID:
26071998
17.

Canine status epilepticus treated with fosphenytoin: A proof of principle study.

Patterson EE, Leppik IE, Coles LD, Podell M, Vite CH, Bush W, Cloyd JC.

Epilepsia. 2015 Jun;56(6):882-7. doi: 10.1111/epi.12994. Epub 2015 May 7.

18.

Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus.

Coles LD, Leppik IE, Patterson EE, Rivers Z, Mishra U, Cloyd JC.

Epilepsia. 2015 Jun;56(6):888-94. doi: 10.1111/epi.12961. Epub 2015 May 7.

19.

Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.

Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, Birnbaum AK.

J Clin Pharmacol. 2015 Oct;55(10):1101-8. doi: 10.1002/jcph.522. Epub 2015 Aug 18.

20.

Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials.

Leppik IE, Wechsler RT, Williams B, Yang H, Zhou S, Laurenza A.

Epilepsy Res. 2015 Feb;110:216-20. doi: 10.1016/j.eplepsyres.2014.11.015. Epub 2014 Dec 13.

21.

Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers.

Ahmed GF, Marino SE, Brundage RC, Pakhomov SV, Leppik IE, Cloyd JC, Clark A, Birnbaum AK.

Br J Clin Pharmacol. 2015 May;79(5):820-30. doi: 10.1111/bcp.12556.

22.

Treating epilepsy in the elderly: more art than science.

Leppik IE, Birnbaum AK.

Cleve Clin J Med. 2014 Aug;81(8):499-500. doi: 10.3949/ccjm.81a.14030. No abstract available.

PMID:
25085988
23.

Safety of an intravenous formulation of lamotrigine.

Conway JM, Birnbaum AK, Leppik IE, Pennell PB, White JR, Rarick JO, Remmel RP.

Seizure. 2014 May;23(5):390-2. doi: 10.1016/j.seizure.2014.01.019. Epub 2014 Jan 31.

24.

Epilepsy, behavior, and art (Epilepsy, Brain, and Mind, part 1).

Rektor I, Schachter SC, Arzy S, Baloyannis SJ, Bazil C, Brázdil M, Engel J Jr, Helmstaedter G, Hesdorffer DC, Jones-Gotman M, Kesner L, Komárek V, Krämer G, Leppik IE, Mann MW, Mula M, Risse GL, Stoker GW, Kasteleijn-Nolst Trenité DG, Trimble M, Tyrliková I, Korczyn AD.

Epilepsy Behav. 2013 Aug;28(2):261-82. doi: 10.1016/j.yebeh.2013.03.011. Epub 2013 Jun 10. Review.

PMID:
23764495
25.

Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.

Clark AM, Kriel RL, Leppik IE, White JR, Henry TR, Brundage RC, Cloyd JC.

Epilepsia. 2013 Jun;54(6):1106-11. doi: 10.1111/epi.12165. Epub 2013 Apr 15.

26.

Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers.

Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC, Cloyd JC.

Epilepsia. 2013 Jun;54(6):1099-105. doi: 10.1111/epi.12134. Epub 2013 Mar 18.

27.

Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.

Ahmed GF, Brundage RC, Marino SE, Cloyd JC, Leppik IE, Pennell PB, Ramsay RE, Birnbaum AK.

J Clin Pharmacol. 2013 Mar;53(3):276-84. doi: 10.1002/jcph.8. Epub 2013 Feb 13.

28.

Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK.

Pharmacogenomics. 2013 Jan;14(1):35-45. doi: 10.2217/pgs.12.180.

29.

Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations.

Leppik IE, Hovinga CA.

Epilepsia. 2013 Jan;54(1):28-35. doi: 10.1111/epi.12043. Epub 2012 Nov 28. Review.

30.

Challenges of epilepsy in elderly people.

Leppik IE, Walczak TS, Birnbaum AK.

Lancet. 2012 Sep 29;380(9848):1128-30. doi: 10.1016/S0140-6736(12)61517-7. No abstract available.

PMID:
23021270
31.

The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.

Marino SE, Pakhomov SV, Han S, Anderson KL, Ding M, Eberly LE, Loring DW, Hawkins-Taylor C, Rarick JO, Leppik IE, Cibula JE, Birnbaum AK.

Epilepsy Behav. 2012 Jul;24(3):365-72. doi: 10.1016/j.yebeh.2012.04.120. Epub 2012 May 30.

32.

Variability of carbamazepine and valproate concentrations in elderly nursing home residents.

Birnbaum AK, Conway JM, Strege MA, Leppik IE.

Epilepsy Res. 2012 Aug;101(1-2):22-7. doi: 10.1016/j.eplepsyres.2012.02.014. Epub 2012 Mar 30.

33.

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs.

Hardy BT, Patterson EE, Cloyd JM, Hardy RM, Leppik IE.

J Vet Intern Med. 2012 Mar-Apr;26(2):334-40. doi: 10.1111/j.1939-1676.2011.00868.x. Epub 2012 Feb 1.

34.

Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, Ramsay RE, Pennell PB, White JR, Gross CR, Rarick JO, Mishra U, Cloyd JC.

Clin Pharmacol Ther. 2012 Mar;91(3):483-8. doi: 10.1038/clpt.2011.251. Epub 2012 Jan 25.

35.

Canine status epilepticus: a translational platform for human therapeutic trials.

Leppik IE, Patterson EN, Coles LD, Craft EM, Cloyd JC.

Epilepsia. 2011 Oct;52 Suppl 8:31-4. doi: 10.1111/j.1528-1167.2011.03231.x.

36.

Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.

Aliwarga T, Cloyd JC, Goel V, Brundage RC, Marino SE, Leppik IE, Remmel RP.

Ther Drug Monit. 2011 Feb;33(1):56-63. doi: 10.1097/FTD.0b013e3182081089.

PMID:
21233690
37.

Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics.

Leppik IE, Goel V, Rarick J, Nixdorf DR, Cloyd JC.

Epilepsy Res. 2010 Oct;91(2-3):289-92. doi: 10.1016/j.eplepsyres.2010.07.016. Epub 2010 Aug 14.

PMID:
20708904
38.

Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.

White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK.

Neurology. 2010 Aug 10;75(6):513-8. doi: 10.1212/WNL.0b013e3181eccfb5.

39.

Epilepsy in the elderly.

Leppik IE, Birnbaum AK.

Ann N Y Acad Sci. 2010 Jan;1184:208-24. doi: 10.1111/j.1749-6632.2009.05113.x. Review.

40.

Canine status epilepticus: Proof of principle studies.

Leppik IE, Patterson E, Hardy B, Cloyd JC.

Epilepsia. 2009 Dec;50 Suppl 12:14-5. doi: 10.1111/j.1528-1167.2009.02362.x. No abstract available.

41.

Characterization of the time course of carbamazepine deinduction by an enzyme turnover model.

Punyawudho B, Cloyd JC, Leppik IE, Ramsay RE, Marino SE, Pennell PB, White JR, Birnbaum AK.

Clin Pharmacokinet. 2009;48(5):313-20. doi: 10.2165/00003088-200948050-00003.

42.

Long-term use of felbamate: clinical outcomes and effect of age and concomitant antiepileptic drug use on its clearance.

White JR, Leppik IE, Beattie JL, Walczak TS, Tran TA, Rarick JO, Vaher P.

Epilepsia. 2009 Nov;50(11):2390-6. doi: 10.1111/j.1528-1167.2009.02187.x. Epub 2009 Jun 26.

43.

Safety of an IV formulation of carbamazepine.

Conway JM, White JR, Birnbaum AK, Eugene Ramsay R, Pennell PB, Rarick JO, Musib L, Leppik IE, Cloyd JC.

Epilepsy Res. 2009 Apr;84(2-3):242-4. doi: 10.1016/j.eplepsyres.2009.01.013. Epub 2009 Mar 18.

44.

Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.

Ahn JE, Cloyd JC, Brundage RC, Marino SE, Conway JM, Ramsay RE, White JR, Musib LC, Rarick JO, Birnbaum AK, Leppik IE.

Neurology. 2008 Jul 1;71(1):38-43. doi: 10.1212/01.wnl.0000316392.55784.57.

PMID:
18591503
45.

Treatment of epilepsy in the elderly.

Leppik IE.

Curr Treat Options Neurol. 2008 Jul;10(4):239-45.

PMID:
18579010
46.

Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics.

Patterson EE, Goel V, Cloyd JC, O'Brien TD, Fisher JE, Dunn AW, Leppik IE.

J Vet Pharmacol Ther. 2008 Jun;31(3):253-8. doi: 10.1111/j.1365-2885.2008.00948.x.

PMID:
18471147
47.

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E.

Epilepsia. 2008 Jul;49(7):1239-76. doi: 10.1111/j.1528-1167.2008.01561.x.

48.

Differential genotype dependent inhibition of CYP2C9 in humans.

Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS.

Drug Metab Dispos. 2008 Jul;36(7):1242-8. doi: 10.1124/dmd.108.020396. Epub 2008 Mar 31.

49.

Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents.

Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE.

Ther Drug Monit. 2007 Oct;29(5):571-5.

PMID:
17898646
50.

Carbamazepine dose-concentration relationship in elderly nursing home residents.

Birnbaum AK, Conway JM, Hardie NA, Lackner TE, Bowers SE, Leppik IE.

Epilepsy Res. 2007 Oct;77(1):31-5. Epub 2007 Sep 24.

PMID:
17890057

Supplemental Content

Loading ...
Support Center